Research programme: stearoyl CoA desaturase inhibitors - iNovacia
Latest Information Update: 07 Feb 2011
At a glance
- Originator Biovitrum
- Developer iNovacia
- Class
- Mechanism of Action Stearoyl-CoA desaturase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Liver disorders; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 07 Feb 2011 Discontinued - Preclinical for Liver disorders in Sweden (unspecified route)
- 07 Feb 2011 Discontinued - Preclinical for Obesity in Sweden (unspecified route)
- 07 Feb 2011 Discontinued - Preclinical for Type-2 diabetes mellitus in Sweden (unspecified route)